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Introduction
Pneumonia remains a common cause of morbidity and mortality 
in the US. Published data from the Centers for Disease Control 
and Prevention ranks pneumonia as the first leading cause of 
death from infectious diseases and eight from all diseases [1]. 
A total of 53,282 individuals died of pneumonia in 2013 [2]. 
Based on the most recent report from the Agency for Healthcare 
Research and Quality, pneumonia was the second most common 
reason for hospital admissions after liveborn (newborn) in 2011 
with over 1.1 million hospitalizations [3]. Another study reported 
3.9 million hospitalizations due to pneumonia between 2007 
and 2011 [4]. CAP has traditionally been considered an acute 
process that, once resolved, has no further impact on patients’ 
survival. Studies evaluating clinical outcomes have focused on 
early mortality; either during hospitalization or within 30 days 
after the initial episode. Early mortality rates range from 4 - 30% 
depending on the studied population, treatment setting, and 
severity of disease [5–8]. Considering this short-term impact 
on patients’ outcomes, CAP research has been traditionally 
focused on improving short-term outcomes such as time to 
clinical stability, clinical failure, length of stay, in-hospital 
mortality, and 30-day mortality. Different immunomodulatory 
strategies including corticosteroids, antiplatelets, and specific 
antibiotics have been considered as interventions, sometimes in 
a particular setting or type of patient [9–12]. 
More recently, data have emerged showing that patients 
surviving an episode of CAP are at increased risk of death long
after hospital discharge [13–26]. In this descriptive review, 
we examine the current knowledge of long-term mortality and 
propose a hypothesis explaining the pathogenesis of long-term 
mortality in patients with CAP. A search was performed using 
MEDLINE/PubMed through April 2017 with the following 
keywords: community-acquired pneumonia, mortality, long-
term, outcomes. 
In an attempt to standardize the follow-up period, we only 
included in this review original studies that either reported 
mortality at 1 year or had enough data to estimate this 
information.  
Current Literature
A total of 21 articles reporting long-term mortality data after 
hospitalizations for CAP were identified, with rates up to 10 or 
more years ranging between 17 and 50%, and up to 2-3 times 
higher than patients without a hospitalization for CAP [13–33]. 
After the initial review, we identified 15 articles reporting 1-year 
mortality rates. In Table 1 we summarized studies describing 
1-year mortality in patients with CAP [13–19]. In Table 2 we 
summarized studies comparing 1-year mortality in patients 
with CAP to control groups [20–27]. Figure 1 represents the 
reported 1-year mortality for hospitalized patients with CAP 
for each study. These studies suggest that for all hospitalized 
patients with CAP, the 1-year mortality is approximately 30 to 
35%. For hospitalized patients without CAP, the 1-year mortality 
is approximately 20 to 25%, whereas for those patients not 
hospitalized and not developing CAP the 1-year mortality was 
even lower, ranging between 1 and 5%. In hospitalized patients 
with CAP, there is a 10% increased risk for 1-year mortality in 
relation to hospitalized patients with other medical conditions. 
Follow-up periods vary among the different published studies 
evaluating long-term mortality. This, along with differences 
in the studied population, makes comparisons difficult. We 
believed that different exclusion criteria among the studies is 
the likely explanation for the wide range mortality reported in 
the studies.
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Table 1 Studies evaluating 1-year mortality after hospitalization due to CAP without a control group
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Author Study criteria Study 
subjects
1-year mortality
Waterer
(2004)19
• Prospective
• Subjects: age ≥ 18 years old hospitalized with CAP (Healthcare organization hospitals - Memphis, TN)
• Pneumonia definition: acute illness (< 14 days of symptoms) with a positive chest image plus one criterion of Group A or two of Group B: 
Group A
 Fever > 37.8°C or Hypothermia < 36°C ✓ Cough or sputum production
Group B
 Dyspnea ✓ Pleuritic chest pain                 
 Physical findings of lung consolidation ✓ Leukocyte count > 12 x 10/L or < 4.5 x 10/L
• Exclusion criteria: AIDS, chemotherapy in the past 60 days, treatment with immunosuppressive medication, non-ambulatory nursing home 
patients, hospitalization within the prior 30 days. 
N= 366 Not provided
Estimated by age group
18-40: 4%
41-60: 8%
61-80: 20%
≥81: 30%
El Solh
(2006)15
• Prospective, observational
• Subjects: age ≥ 65 years old hospitalized with CAP (single center - Buffalo, NY)
• Pneumonia definition: positive chest image plus at least 2 of the following: 
 Cough ✓ Dyspnea
 Chest pain ✓ Change in mental status
and at least 1 of the following: 
 Temperature ≥ 38°C or ≤ 36°C
 Leukocytosis (>11.0 x 109/L) or leukopenia (<3.5.0 x 109/L)
and absence of evidence of a cause other than pneumonia
• Exclusion criteria: nursing home residents, hospitalization in the prior 90 days, aspiration, severe immunosuppression (solid organ 
transplantation, HIV/AIDS, steroid therapy > 10 mg/d for > 2 weeks), underlying active malignancy,  or do-nor resuscitate order
N= 301 10%
Johnstone
(2008)17
• Secondary analysis of prospective (implementation of a critical pathway for the management of CAP)
• Subjects: age ≥ 18 years old hospitalized with CAP (all 6 hospitals - Alberta, Canada)
• Pneumonia definition: positive chest image plus at least 2 of the following: 
 Temperature > 38°C ✓ Chest pain
 Productive cough ✓ Crackles on auscultation
 Shortness of breath
• Exclusion criteria: immune deficiency (HIV, use of > 10 mg/d of prednisone or other immunosuppressive agents, active treatment for 
cancer, history of organ transplantation, active TB, cystic fibrosis), shock, intubation or direct ICU admission, pregnant or breastfeeding 
women, alcohol addiction, chronic renal failure
N= 3,284 28%
Cecere 
201014
• Prospective, observational
• Subjects: age ≥ 18 years old hospitalized with CAP (1 hospital - Washington, SA)
• Pneumonia definition: positive chest image plus either: 
≥1 major criterion
 Cough ✓ Sputum production
 Fever (>37.9°C) or hypothermia (<35.0°C) ✓ Crackles on auscultation
≥2 minor criteria
 Pleuritic chest pain ✓ Dyspnea
 Altered mental status ✓ Abnormal chest examination findings
 Leukocytosis (white blood cell count >12,000 cells/mL), or left shift (>10% band forms)
• Exclusion criteria: transferred from another hospital, were hospitalized within 7 days before the index admission, were admitted for 
terminal care, or refused to give consent                          
N= 457 15% 
Estimated from survival
analysis
Koskela
201418
• Prospective, observational 
• Subjects: age ≥ 18 years old hospitalized with CAP (1 hospital – Kuopio, Finland)
• Pneumonia definition: acute febrile illness with a new radiographic shadowing (referencing BTS guidelines 2009)
• Exclusion criteria: severe pneumonia requiring ICU, refused to give consent, antibiotic treatment started in another institution
N= 153 5%
Estimated from survival 
analysis
Adamuz
201413
• Prospective, observational
• Subjects: age ≥ 18 years old hospitalized with CAP (1 hospital - Barcelona, Spain)
• Pneumonia definition: not listed
• Exclusion criteria: neutropenia, immunoglobulin deficiencies, HIV infection, transplantation or splenectomy, receiving 
immunosuppressant and/or corticosteroid therapy (>20 mg/day of prednisone or its equivalent)
N= 1,284 7.2%
Holter
201616
• Subjects: age ≥ 18 years old hospitalized with CAP (South-Eastern Norway)
• Pneumonia definition: positive chest image plus: 
 Rectal temperature >38.0°C
 At least one of the following symptoms or signs:
 Cough (productive or non-productive) ✓ Dyspnea
 Chest pain ✓ Crackles or reduced respiratory sounds
• Exclusion criteria: non-infectious causes (pulmonary infarction, tumor or bronchiectasis) or if the patient had been hospitalized within the 
past 2 weeks.             
N= 259 9%
Table 2 Studies evaluating 1-year mortality after hospitalization due to CAP with a control group
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Author CAP cases Controls 1-year mortality
Koivula
199925
N= 122 
• Subjects: age ≥ 60 years old enrolled in a randomized, pneumococcal vaccination trial in Finland
• Pneumonia definition: positive chest image plus one of the following: 
 Temperature over 38.7°C and new or worsening cough PLUS one of the following: moist rales, dyspnea, 
tachypnea, cyanosis, pain in the chest or abdomen at respiration, purulent or blood stained sputum, acute 
deterioration of the general condition   
 ≥2 of the following:  temperature over 38.7°C, new/worsening cough plus moist rales, dyspnea, tachypnea, or 
cyanosis, pain in the chest or abdomen at respiration, purulent or blood stained sputum
 New or worsening cough and temperature over 38°C for more than 5 days.
• Exclusion criteria: none
N= 4,045
• Subjects enrolled in same 
randomized, pneumococcal 
vaccination trial in Finland 
who did not develop 
pneumonia
CAP: 19%
Controls: 4%
Kaplan 
200324
N= 158,960
• Subjects: age ≥ 65 years old from the 1997 Medicare hospital discharge database
• CAP definition: ICD-9 codes 481, 482, 485, or 486 listed both at admission and discharge plus a pulmonary complaint on 
admission (ICD-9 518.81, 496, 786.09, 491.21, 507.0, 466.0, 786.3, 493.90, 786.3, 518.82)
• Exclusion criteria: transferred from other hospitals
N= 794,333
• Five age, sex, and race 
matched from the same 
database who did not meet 
ICD-9 criteria
CAP: 34%
Controls: 25%
Carriere
200422
N= 43,642
• Subjects: age ≥ 18 years old from 2 Canadian (Alberta Province) administrative health service databases
• CAP definition: ICD-9 codes 480.0 - 487.8 (pneumonia) or 507.0 – 507.8 (aspiration pneumonia)
• Exclusion criteria: ICD-9 codes 484.1 – 484.7, non-Alberta residents, not treated in an Alberta acute care facility, 
previous hospitalization within 10 days 
N= 1,950,997
• Alberta general population 
not hospitalized with 
pneumonia in 1994/1995
CAP: 26 %
Controls: 5%
Percentages
estimated from 
data in manuscript
Bordon 
201020
N= 624
• Subjects: age ≥ 18 years old admitted to VA hospital
• CAP definition: positive chest image plus ≥1 of the following: 
 New or increased cough ✓ Abnormal temperature
 Abnormal serum leukocyte count
• Exclusion criteria: none         
N= 6,347
• Hospitalized patients during 
same period due to medical 
conditions other than CAP
CAP: 32%
Controls: 20%
Percentages
estimated from 
data in manuscript
Bruns 
201021
N= 356
• Subjects: age ≥ 18 years old prospective cohort derived from two randomized clinical trials
• CAP definition: positive chest image plus ≥2 of the following:
 Cough
 Sputum production
 Rectal temperature> 38°C or < 36.1°C
 Auscultatory findings consistent with pneumonia
 Leukocytosis  (>109 white blood cells/litre or > 15% bands)
 Positive culture of blood or pleural fluid 
 C reactive protein more than three times the upper limit of normal
• Exclusion criteria: mechanical ventilation in an intensive care unit, cystic fibrosis; a history of colonization with Gram-
negative bacteria due to structural damage to the respiratory tract; malfunction of the digestive tract; life expectancy 
of less than one month because of underlying disease, infections other than pneumonia that needed antibiotic 
treatment, severe immunosuppression 
N= 356
• Age and sex matched general 
population cohort
CAP: 17%
Controls: 4%
Sandvall
201426
N= 392
• Subjects: age ≥ 18 years old admitted to VA hospital with Streptococcal pneumonia
• CAP definition: positive chest image plus ≥1 of the following: 
 Subjective fever ✓ Cough
 Sputum production ✓ Pleuritic chest pain
• Exclusion criteria: none    
N= not documented
• Expected 1-year survival of 
an average 63-year-old 
American male from the 
Human mortality database
CAP: 15%
Controls: 1%
Percentages
estimated from 
data in manuscript
Eurich
201523
N= 6,078
• Subjects: Age: ≥ 18 years old enrolled in a clinical registry
• CAP definition: positive chest image plus ≥2 of the following: 
 Cough
 Pleuritic chest pain
 Shortness of air
 Temperature >38°C
 Crackles on auscultation
• Exclusion criteria: immune deficiency, shock, mechanical ventilation on admission, pregnancy, breastfeeding, 
alcoholism, chronic renal disease.   
N= 29,402
• Age and sex matched
• Alive at time of CAP case
• Presenting to the hospital 
within the same month/year 
with a non-pneumonia 
diagnosis
• No history of CAP in the prior 
year
CAP: 13%
Controls: 5%
Percentages
estimated from 
data in manuscript
Mangen
201727
N= 562
• Subjects: age ≥ 65 years old enrolled in a pneumococcal vaccine study
• CAP definition: positive chest image plus a positive PCV 13 vaccine-type–specific urinary antigen test or isolation of 
vaccine-type S. pneumoniae from blood or another sterile site, plus the presence of ≥2 of the following:
 Cough
 Production of purulent sputum or a change in the character of sputum
 Temperature >38.0°C or <36.1°C
 Auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation
 Leukocytosis (>109 white blood cells/liter or >15% bands)
 C-reactive protein >3 times the upper limit of normal
 Hypoxemia with a partial oxygen pressure (PO2) <60 mm Hg while the patient is breathing room air
• Exclusion criteria: previous vaccination with any pneumococcal vaccine, residence in long-term care facility,
contraindication for 13vPnC, contraindication for influenza vaccines, use of investigational products in 30 days prior to 
study vaccine administration, history of severe adverse reaction associated with any vaccine component,
immunodeficiency or immune suppression.  
N= 1,123
• Age and sex matched 
subjects enrolled in the same
vaccination trial without 
pneumonia
CAP: 8%
Controls: 1%
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Fig. 1 Forest plot display of studies evaluating 1-year mortality after hospitalization for CAP
A hypothesis to explain long-term 
mortality
Chronic inflammation has been associated with aging and 
early death; a process described as “inflammaging” [34]. 
Persistent elevated levels of inflammatory cytokines have been 
documented in patients with CAP at time of hospital discharge. 
The increased long-term mortality after CAP may be mediated 
by an inflammatory response that persists after hospital 
discharge, adds to the inflammaging process, and accelerates 
the progression of medical comorbidities and early death 
[35, 36]. Months after hospital discharge, the primary cause 
of death may be cardiovascular disease or other underlying 
comorbidities. The prior episode of CAP would influence 
death by worsening the underlying comorbidity. Figure 2 
is a schematic representation indicating the projectedlife 
expectancy of a 50-year old patient who is hospitalized due to 
CAP (Figure 2: point 1). After the patient is discharged from 
the hospital, the projected life expectancy changes to line B and 
is considerably decreased (Figure 2: point 2). 
Mortality rates for patients with CAP have not significantly 
decreased since the 1950s [37]. Adjunctive therapies such as 
macrolides, statins, corticosteroids, and antiplatelet agents 
have been studied in an attempt to improve short-term 
outcomes [38]. Despite the knowledge of higher mortality 
rates long after hospitalization for CAP, no studies evaluating 
the impact of adjunctive therapies on longterm outcomes have 
been conducted. It can be speculated that medications able to 
decrease chronic inflammation may reduce long term mortality 
in hospitalized patients with CAP. 
Fig. 2 Schematic representation of the change in life expectancy for a 
patient hospitalized with CAP
Conclusions
Improving the clinical outcomes of hospitalized patients 
with CAP is of paramount importance for patients, as well 
as clinical investigators. The recent recognition of long-term 
mortality associated with CAP is opening a new frontier for 
clinical research in the field. We need studies to better define 
the underlying pathophysiology explaining the association of 
CAP with long-term mortality. Intervention to improve clinical 
outcomes in patients with CAP have frequently been tested in 
short term 30-day studies, since CAP was considered an acute 
problem without chronic implications. We need a new paradigm 
to design clinical trials to test interventions that may reduce 
long-term mortality.
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